SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$113M
Q1 2020
Positions
46
Filings on Record
39
2019–present window
Filed
May 12, 2020
original filing

Summary

Birchview Capital, LP reported $113M in U.S.-listed holdings across 46 positions for Q1 2020.

The portfolio is heavily concentrated: BMY alone accounts for 38.9% of reported value.

Compared with Q4 2019, the fund opened 5 new positions and exited 11.

Portfolio Metrics

Turnover
+11.8%
vs prior filed quarter
Top-10 Concentration
+80.3%
share of reported value
Largest Position
+38.9%
Bristol Myers Squibb
New / Exited
5 / 11
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 74.5%Other: 22.5%Right: 2.4%MLP: 0.5%
  • Common Stock · 74.5% · $84M
  • Other · 22.5% · $25M
  • Right · 2.4% · $3M
  • MLP · 0.5% · $605,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GILDGILEAD SCIENCES INCNEW+20.0K20.0K+$1M$1M
EPZMEUREPIZYME INCNEW+60.0K60.0K+$931,000$931,000
STOKSTOKE THERAPEUTICS INCNEW+20.0K20.0K+$458,000$458,000
INFLARX NVNEW+110.0K110.0K+$420,000$420,000
TRANSLATE BIO INCNEW+30.0K30.0K+$299,000$299,000
ACADACADIA PHARMACEUTICALS INCADDED+78.0K92.0K+$3M$4M
UTHUNITED THERAPEUTICS CORPADDED+13.0K18.0K+$1M$2M
AMARIN CORP PLCADDED+121.0K180.0K−$545,000$720,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

46 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM38.85%$44M785.8K
2ACCELERATE DIAGNOSTICS INCCOM16.21%$18M2.19M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM5.68%$6M74.0K
4QDEL*QUIDEL CORPhistory →COM4.24%$5M48.8K
5ACADACADIA PHARMACEUTICALS INChistory →COM3.45%$4M92.0K
6BIIBBIOGEN INChistory →COM3.09%$3M11.0K
7KPTIEURKARYOPHARM THERAPEUTICS INChistory →COM2.52%$3M148.0K
8BMY-RBMY CVR RTS 03/31/21history →RIGHT2.38%$3M706.8K
9VERMILLION INCCOM2.38%$3M3.22M
10UTHUNITED THERAPEUTICS CORPhistory →COM1.51%$2M18.0K
11XLRNACCELERON PHARMA INChistory →COM1.49%$2M18.7K
12OXFORD IMMUNOTEC GLOBAL PLCCOM1.40%$2M170.3K
13GILDGILEAD SCIENCES INChistory →COM1.33%$1M20.0K
14CFRXEURCONTRAFECT CORPhistory →COM1.31%$1M255.7K
15MASI*MASIMO CORPhistory →COM1.26%$1M8.0K
16CCXIEURCHEMOCENTRYX INChistory →COM1.07%$1M30.0K
17EPZMEUREPIZYME INCCOM0.83%$931,00060.0K
18ARNAEURARENA PHARMACEUTICALS INCCOM0.82%$924,00022.0K
19VNDAVANDA PHARMACEUTICALS INCCOM0.74%$829,00080.0K
20BDQMALBIREO PHARMA INCCOM0.70%$786,00048.0K
21AMARIN CORP PLCSPONS ADR NEW0.64%$720,000180.0K
22HROWHARROW HEALTH INCCOM0.61%$688,000180.0K
23IMGNEURIMMUNOGEN INCCOM0.57%$648,000190.0K
24EQMUSDEQM MIDSTRM PRTNERS LP LTDUNIT LTD PARTN0.54%$605,00051.3K
25ARVNARVINAS INCCOM0.54%$604,00015.0K
26HTDCORCEPT THERAPEUTICS INCCOM0.53%$594,00050.0K
27ODONATE THERAPEUTICS INCCOM0.49%$552,00020.0K
28ICPTUSDINTERCEPT PHARMACEUTICALS INCCOM0.46%$523,0008.3K
29SOLENO THERAPEUTICS INCCOM0.43%$480,000201.5K
30STOKSTOKE THERAPEUTICS INCCOM0.41%$458,00020.0K
31GTHXEURG1 THERAPEUTICS INCCOM0.39%$441,00040.0K
32INFLARX NVCOM0.37%$420,000110.0K
33XNCRXENCOR INCCOM0.33%$368,00012.3K
34AM6AMICUS THERAPEUTICS INCCOM0.31%$351,00038.0K
35BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.30%$340,00010.0K
36PGNYPROGYNY INCCOM0.28%$318,00015.0K
37TRANSLATE BIO INCCOM0.27%$299,00030.0K
38VYGRVOYAGER THERAPEUTICS INCCOM0.24%$274,00030.0K
39PXDEURPIONEER NATURAL RESOURCES COCOM0.24%$267,0003.8K
404XC1KALVISTA PHARMACEUTICALS INCCOM0.20%$230,00030.0K
41APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.19%$214,0008.0K
42DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.16%$184,00010.0K
43TGTXTG THERAPEUTICS INCCOM0.13%$148,00015.0K
44YIELD10 BIOSCIENCE INCCOM0.06%$71,00019.0K
45WKHSEURWORKHORSE GROUP INCCOM0.04%$45,00025.0K
46BCRXBIOCRYST PHARMACEUTICALS INCCOM0.04%$40,00020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.